Approval · Notice of Compliance 14126 · 2013
EXJADE: Notice of Compliance 14126
Issued February 8, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14126
- Date
- February 8, 2013
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Product Mmonograph
- Therapeutic class
- Iron chelating agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXJADE | Not yet assigned | — |
Medicinal ingredients
- DEFERASIROX 125 MG per TAB
- DEFERASIROX 250 MG per TAB
- DEFERASIROX 500 MG per TAB